Zura Bio's Phase 2 TibuSHIELD study misses primary endpoint; HS program discontinued

Zura Bio said its Phase 2 TibuSHIELD study of tibulizumab in moderate-to-severe hidradenitis suppurativa did not meet its primary endpoint at Week 16 at either dose, and key secondary endpoints were also not met. Based on the results, the company is discontinuing development of tibulizumab in HS, while its systemic sclerosis and polymyalgia rheumatica programs continue. The failure removes one indication from the company's lead product candidate.

Key points

• Primary endpoint (percentage change from baseline in abscess and inflammatory nodule count) not met: 56.0% reduction at 300 mg and 58.1% at 150 mg, versus 52.5% for placebo
• HiSCR50 response was 48.0% (300 mg) and 52.7% (150 mg) versus 45.5% for placebo; HiSCR75 was 35.3% and 34.0% versus 28.1%
• Trial enrolled 247 participants; both doses were well tolerated per the company, with one death in the 300 mg arm judged unrelated to treatment by the site investigator
• As of September 30, 2026, cash and cash equivalents were $187.7 million, expected to fund operations through at least the end of 2028; TibuSURE topline data expected in H1 2027

The filing

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:16 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.